Employees: 1,236
Size Zhejiang Anglikang Pharmaceutical (002940.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $612M, the 3195th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥20.85 on 18 Nov 2026.
Performance Over six months the shares fell 51.8%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 13.5% over the last twelve months (peer median +4.6%); the operating margin is 10.0% (peer median 4.1%).
Valuation It trades at 3.3× enterprise value to sales against a peer median of 3.3× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.3 points above its cost of capital (6.5% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.27B | CN¥1.42B | CN¥1.52B | CN¥1.61B | CN¥1.55B |
| Revenue growth | — | -7% | -5% | +4% | — |
| Gross profit | CN¥529M | CN¥527M | CN¥574M | CN¥680M | CN¥864M |
| EBITDA | n/a | CN¥228M | CN¥204M | CN¥242M | CN¥196M |
| Net income | CN¥110M | CN¥125M | CN¥80.3M | CN¥138M | CN¥127M |
| Free cash flow | CN¥166M | CN¥196M | CN¥162M | CN¥155M | CN¥117M |
| Capital expenditure | CN¥58.3M | CN¥49.9M | CN¥94.5M | CN¥125M | CN¥68.8M |
| Total debt | CN¥704M | CN¥733M | CN¥805M | CN¥796M | CN¥570M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002940.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | -10.2% | 10th lowest of 20 |
| 6-month return | -51.8% | -26.6% | 2nd lowest of 20 |
| Distance from 52-week high | -57.4% | -41.0% | 6th lowest of 20 |
| Revenue growth (TTM) | -13.5% | +4.6% | 2nd lowest of 15 |
| Operating margin | 10.0% | 4.1% | 3rd highest of 14 |
| EV / Sales | 3.3× | 3.3× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 10.1% | -0.6% | 4th most demanding of 10 |
| Growth delivered (Del g) | +2.1% | -1.6% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | +8.1 pp | +16.9 pp | 5th least demanding of 10 |
| ROIC minus cost of capital | +0.3 pp | -4.8 pp | 3rd highest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $612M | -52% | -13% | 10% | 3.3× | 10.1% | +2.1% |
| Fuan Pharmaceutical (Group) 300194.SZ | China | $612M | -14% | -3% | -1% | 2.4× | 10.9% | -5.9% |
| HeiLongJiang ZBD Pharmaceutical 603567.SS | China | $610M | -39% | -82% | n/a | 25.1× | 9.1% | -25.1% |
| Orchid Pharma ORCHPHARMA.NS | India | $613M | +30% | +11% | 0% | 6.1× | n/a | n/a |
| Achieve Life Sciences QUIT | United States | $609M | n/a | n/a | n/a | n/a | n/a | n/a |
| Luoxin Pharmaceuticals Group Stock 002793.SZ | China | $609M | -26% | -10% | -9% | 2.0× | -1.0% | -17.9% |
| Chongkundang 185750.KS | South Korea | $609M | -27% | +6% | 4% | 0.5× | -6.6% | +5.4% |
| TTY Biopharm 4105.TWO | Taiwan | $615M | +10% | +5% | 29% | 3.0× | -8.7% | +8.8% |
| Olema Pharmaceuticals OLMA | United States | $619M | -49% | n/a | n/a | n/a | n/a | n/a |
| Hubei Biocause Heilen Pharmaceutical 301211.SZ | China | $619M | -10% | +13% | 4% | 5.3× | n/a | n/a |
| DBV Technologies DBV.PA | France | $604M | -46% | n/a | n/a | n/a | n/a | n/a |
| Shandong Jincheng Pharmaceutical 300233.SZ | China | $604M | -31% | +2% | 4% | 1.2× | -0.6% | -1.6% |
| Hangzhou Bio-Sincerity Pharma-Tech 301096.SZ | China | $602M | -38% | +5% | -30% | 7.5× | n/a | n/a |
| Bicara Therapeutics BCAX | United States | $623M | -54% | n/a | n/a | n/a | n/a | n/a |
| JIANMIN PHARMACEUTICAL 600976.SS | China | $598M | -14% | -2% | 8% | 0.9× | -6.2% | +6.5% |
| Immix Biopharma IMMX | United States | $596M | -20% | n/a | n/a | n/a | n/a | n/a |
| Arbutus Biopharma ABUS | United States | $630M | -6% | +1,143% | 80% | 1.6× | n/a | n/a |
| Zhejiang Wecome Pharmaceutical 300878.SZ | China | $632M | -18% | +92% | -41% | 16.9× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $591M | -41% | +3% | -39% | 3.7× | 50.4% | -12.3% |
| Center Laboratories 4123.TWO | Taiwan | $639M | -29% | +14% | 9% | 12.8× | 36.3% | +16.2% |
| Cullinan Therapeutics CGEM | United States | $585M | -37% | n/a | n/a | n/a | n/a | n/a |